Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer.

Yesterday, March 11, 2015, 115 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $183.00 to $317,250,000.00.

Highlighted Stocks Traded by Insiders:

Equinix (EQIX) - FREE Research Report

Taylor Keith D, who is Chief Financial Officer at Equinix, sold 1,000 shares at $233.57 on March 11, 2015. Following this transaction, the Chief Financial Officer owned 56,596 shares meaning that the stake was reduced by 1.74% with the 1,000-share transaction.

The shares most recently traded at $227.48, down $6.09, or 2.68% since the insider transaction. Historical insider transactions for Equinix go as follows:

  • 4-Week # shares sold: 19,950
  • 12-Week # shares sold: 21,218
  • 24-Week # shares sold: 21,218

The average volume for Equinix has been 627,600 shares per day over the past 30 days. Equinix has a market cap of $12.9 billion and is part of the technology sector and internet industry. Shares are up 0.13% year-to-date as of the close of trading on Wednesday.

Equinix, Inc. is a publicly owned real estate investment trust. The stock currently has a dividend yield of 4.07%. Currently, there are 8 analysts who rate Equinix a buy, no analysts rate it a sell, and 5 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on EQIX - FREE

TheStreet Quant Ratings rates Equinix as a hold. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance and good cash flow from operations. However, as a counter to these strengths, we also find weaknesses including deteriorating net income, disappointing return on equity and generally higher debt management risk. Get the full Equinix Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

Salix Pharmaceuticals (SLXP) - FREE Research Report

Forbes William P, who is President, Medical R&D and CDO at Salix Pharmaceuticals, sold 42,880 shares at $157.84 on March 11, 2015. Following this transaction, the President, Medical R&D and CDO owned 51,714 shares meaning that the stake was reduced by 45.33% with the 42,880-share transaction.

The shares most recently traded at $167.91, up $10.07, or 6% since the insider transaction. Historical insider transactions for Salix Pharmaceuticals go as follows:

  • 4-Week # shares sold: 28,600
  • 12-Week # shares sold: 28,600
  • 24-Week # shares sold: 28,600

The average volume for Salix Pharmaceuticals has been 2.7 million shares per day over the past 30 days. Salix Pharmaceuticals has a market cap of $10.1 billion and is part of the health care sector and drugs industry. Shares are up 46.69% year-to-date as of the close of trading on Wednesday.

Salix Pharmaceuticals, Ltd. acquires, develops, and commercializes prescription drugs and medical devices to treat various gastrointestinal diseases in the United States. Currently, there are 3 analysts who rate Salix Pharmaceuticals a buy, no analysts rate it a sell, and 9 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on SLXP - FREE

TheStreet Quant Ratings rates Salix Pharmaceuticals as a hold. Among the primary strengths of the company is its solid stock price performance. At the same time, however, we also find weaknesses including deteriorating net income, disappointing return on equity and feeble growth in the company's earnings per share. Get the full Salix Pharmaceuticals Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

IsoRay (ISR) - FREE Research Report

Lavoy Thomas C, who is Director at IsoRay, bought 10,000 shares at $1.66 on March 11, 2015. Following this transaction, the Director owned 93,523 shares meaning that the stake was boosted by 11.97% with the 10,000-share transaction.

The shares most recently traded at $1.59, down $0.07, or 4.4% since the insider transaction. Historical insider transactions for IsoRay go as follows:

  • 4-Week # shares bought: 10,029
  • 12-Week # shares bought: 10,029
  • 24-Week # shares bought: 10,029

The average volume for IsoRay has been 513,100 shares per day over the past 30 days. IsoRay has a market cap of $84.0 million and is part of the health care sector and health services industry. Shares are up 6.16% year-to-date as of the close of trading on Wednesday.

IsoRay, Inc develops, manufactures, and sells isotope-based medical products and devices for the treatment of cancer and other malignant diseases in the United States. Currently, there is 1 analyst who rates IsoRay a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ISR - FREE

TheStreet Quant Ratings rates IsoRay as a sell. Among the areas we feel are negative, one of the most important has been poor profit margins. Get the full IsoRay Ratings Report from TheStreet Quant Ratings now.

EXCLUSIVE OFFER: See inside Jim Cramer's multi-million dollar charitable trust portfolio to see the stocks he thinks could be potential winners. Click here to see his holdings for 14-days FREE.

null